Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

9.550 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	9.370 (100)
Ask (Size)	9.380 (500)
Prev. Close	9.550
Today's Range	9.550 - 9.550
52wk Range	1.830 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds ↗

February 26, 2026

Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday.

Via Stocktwits

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Via Stocktwits

Performance

YTD	+372.8%	+372.8%
1 Month	+60.5%	+60.5%
3 Month	+304.7%	+304.7%
6 Month	+309.9%	+309.9%
1 Year	+218.3%	+218.3%

More News

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Via Stocktwits

ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally ↗

February 26, 2026

Via Stocktwits

IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move ↗

February 24, 2026

Via Stocktwits

IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ↗

February 23, 2026

Via Stocktwits

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗

February 23, 2026

Via The Motley Fool

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 23, 2026

Via Chartmill

Why ImmunityBio Stock Is Soaring Again Today ↗

February 23, 2026

Via The Motley Fool

These stocks are gapping in today's session ↗

February 23, 2026

Via Chartmill

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗

February 23, 2026

Via Stocktwits

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Via Stocktwits

IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough ↗

February 23, 2026

Via Stocktwits

ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗

February 20, 2026

Via Stocktwits

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

February 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗

February 20, 2026

Via Stocktwits

IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗

February 20, 2026

Via Stocktwits

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗

February 19, 2026

Via Stocktwits

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

February 19, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

February 19, 2026

Via Stocktwits

Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗

February 18, 2026

Via Stocktwits

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 9.550

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 02/26/26 04:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 3.74B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.